. 2022 Mar 19;11(1):841–849. doi: 10.1080/22221751.2022.2049458

Table 2.

Antimicrobial susceptibility of clinical CRKP and CR-HvKP strains.

Antibiotics	Range	CRKP (n = 784)				CR-HvKP (n = 60)
Antibiotics	Range	MIC₅₀	MIC₉₀	%S	%R	MIC₅₀	MIC₉₀	%S	%R
Ceftazidime	≤4–>128	64	>128	1	99	32	>128	0	100
Cefotaxime	≤4–>128	>128	>128	0	100	>128	>128	0	100
Amikacin	≤4–>128	>128	>128	27	73	>128	>128	18	82
Ciprofloxacin	≤1–>32	>32	>32	2	98	32	>32	0	100
Cefmetazole	≤2–>128	128	>128	2	98	128	>128	0	100
Cefepime	≤4–>64	>64	>64	1	99	>64	>64	0	100
Piperacillin- tazobactam	128/4–>256/4	>256/4	>256/4	0	100	>256/4	>256/4	0	100
Colistin	≤0.5–>8	≤0.5	2	96	4	≤0.5	1	94	6
Imipenem	≤0.5–>128	32	64	1	100	32	64	0	100
Meropenem	2–>128	128	>128	0	100	128	>128	0	100
Ertapenem	8–>128	>128	>128	0	100	128	>128	0	100
Cefoperazone- sulbactam	32/16–>128/64	>128/64	>128/64	0	100	>128/64	>128/64	0	100
Tigecycline^a	≤0.25–4	1	2	79	21	1	2	69	31
Aztreonam	32–>128	>128	>128	0	100	>128	>128	0	100

^{^a}

For tigecycline, NS (non-susceptible) % was used here to replace R% (resistance). The proportion of CRKP and CR-HvKP strains that exhibited intermediate resistance was 19% and 31%, respectively.